派林生物
(000403)
| 流通市值：92.94亿 | | | 总市值：93.90亿 |
| 流通股本：9.41亿 | | | 总股本：9.50亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 829,843,121.92 | 342,919,344.14 | 2,632,607,334.51 | 1,618,146,526.33 |
| 营业总成本 | 733,971,078.38 | 316,465,168.44 | 2,019,433,608.71 | 1,204,150,334.5 |
| 其他经营收益 | | | | |
| 营业利润 | 103,297,591.96 | 31,779,509.93 | 527,210,376.11 | 431,462,687.63 |
| 利润总额 | 98,879,563.65 | 29,076,183.34 | 500,301,403.36 | 406,936,999.45 |
| 净利润 | 84,973,590.59 | 22,731,547.4 | 419,535,951.9 | 357,497,339.78 |
| 每股收益 | | | | |
| 其他综合收益 | -19,747.23 | -9,967.72 | -13,438.93 | -6,950.72 |
| 综合收益总额 | 84,953,843.36 | 22,721,579.68 | 419,522,512.97 | 357,490,389.06 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,914,648,921.98 | 3,550,219,651.07 | 3,721,008,187.98 | 3,775,000,285.1 |
| 非流动资产: | | | | |
| 非流动资产合计 | 5,870,030,291.1 | 5,832,497,555.22 | 5,745,340,888.22 | 5,800,190,956.52 |
| 资产总计 | 9,784,679,213.08 | 9,382,717,206.29 | 9,466,349,076.2 | 9,575,191,241.62 |
| 流动负债: | | | | |
| 流动负债合计 | 1,286,505,150.46 | 1,052,647,088.67 | 1,128,483,404.02 | 1,286,570,539.25 |
| 非流动负债: | | | | |
| 非流动负债合计 | 448,027,723.86 | 226,099,609.17 | 256,616,743.41 | 269,453,897.51 |
| 负债合计 | 1,734,532,874.32 | 1,278,746,697.84 | 1,385,100,147.43 | 1,556,024,436.76 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 8,056,252,246.81 | 8,110,986,336.05 | 8,088,027,470.57 | 8,025,948,717.19 |
| 股东权益合计 | 8,050,146,338.76 | 8,103,970,508.45 | 8,081,248,928.77 | 8,019,166,804.86 |
| 负债和股东权益合计 | 9,784,679,213.08 | 9,382,717,206.29 | 9,466,349,076.2 | 9,575,191,241.62 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,134,635,545.91 | 480,097,281.63 | 2,165,748,405.96 | 1,675,909,944.71 |
| 经营活动现金流出小计 | 1,218,507,304.35 | 651,948,836.77 | 2,381,739,019.22 | 1,772,396,789.8 |
| 经营活动产生的现金流量净额 | -83,871,758.44 | -171,851,555.14 | -215,990,613.26 | -96,486,845.09 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 481,829,352.72 | 316,040,553.6 | 1,552,086,245.39 | 934,875,655.73 |
| 投资活动现金流出小计 | 679,982,470.37 | 443,776,304.86 | 1,783,403,421.77 | 1,510,279,572.61 |
| 投资活动产生的现金流量净额 | -198,153,117.65 | -127,735,751.26 | -231,317,176.38 | -575,403,916.88 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 658,102,000 | 103,500,000 | 771,307,747.13 | 534,368,741.72 |
| 筹资活动现金流出小计 | 397,502,486.55 | 138,509,815.61 | 874,813,259.66 | 609,997,665.17 |
| 筹资活动产生的现金流量净额 | 260,599,513.45 | -35,009,815.61 | -103,505,512.53 | -75,628,923.45 |
| 汇率变动对现金及现金等价物的影响 | -62,263.45 | -31,771.38 | 49,364.89 | -23,583.88 |
| 现金及现金等价物净增加额 | -21,487,626.09 | -334,628,893.39 | -550,763,937.28 | -747,543,269.3 |
| 期末现金及现金等价物余额 | 748,108,991.24 | 434,967,723.94 | 769,596,617.33 | 572,817,285.31 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -21,487,626.09 | - | -550,763,937.28 | - |